

AMENDMENTS TO THE CLAIMS

1. (cancelled)

2. (previously presented) An isolated polypeptide having an amino acid sequence of natural human Fas ligand (SEQ ID NO:17) wherein the 129th amino acid and 130th amino acid residues as measured from N terminal end are both deleted, and at least one amino acid residue from 111th amino acid to 128th amino acid residues or at least one amino acid residue from 131st amino acid to 133rd amino acid residues as measured from N terminal end is deleted.

2. (previously presented) An isolated polypeptide having an amino acid sequence of natural human Fas ligand (SEQ ID NO:17) wherein all of the 8th amino acid to 69th amino acid residues as measured from N terminal end are deleted, 129th amino acid and 130th amino acid residues as measured from N terminal end are both deleted, and at least one amino acid residue from 111th amino acid to 128th amino acid residues or at least one amino acid residues from 131st amino acid to 133rd amino acid residues as measured from N terminal end is deleted.

3. (currently amended) ~~A novel~~ An isolated polypeptide including the amino acid sequence described in SEQ ID NO:1 or 2.

~~4~~ 5. (previously presented) An isolated DNA coding for the polypeptide of claim ~~2~~.

6. (cancelled)

7. (cancelled)

~~5~~ 8. (previously presented) An isolated DNA coding for the polypeptide of claim ~~2~~.

~~6~~ 9. (previously presented) An isolated DNA coding for the polypeptide of claim ~~2~~.

~~7~~ 10. (previously presented) An isolated polypeptide having an amino acid sequence of natural human Fas ligand (SEQ ID NO:17) wherein the 129th amino acid and 130th amino acid residues as measured from N terminal end are both deleted, and at least one amino acid residue from 111th amino acid to 128th amino acid residues or at least one amino acid residue from 131st amino acid to 133rd amino acid residues as measured from N terminal end is deleted, wherein said polypeptide has membrane binding activity and induces Fas-mediated apoptotic activity.

~~8~~ 11. (previously presented) An isolated polypeptide having an amino acid sequence of natural human Fas ligand (SEQ ID NO:17) wherein all of the 8th amino acid to 69th amino acid residues as

measured from N terminal end are deleted, 129th amino acid and 130th amino acid residues as measured from N terminal end are both deleted, and at least one amino acid residue from 111th amino acid to 128th amino acid residues or at least one amino acid residues from 131st amino acid to 133rd amino acid residues as measured from N terminal end is deleted, wherein said polypeptide has membrane binding activity and induces Fas-mediated apoptotic activity.

9/12. (previously presented) An isolated peptide having an amino acid sequence of natural human Fas ligand (SEQ ID NO:17) wherein at least four amino acid residues, including 128th and 131st amino acid residues are continuously deleted from the 111th amino acid to the 133rd amino acid residues as measured from N terminal end. ~~wherein the 129th amino acid and 130th amino acid residues as measured from N terminal end are both deleted, and at least one amino acid residue from 111th amino acid to 128th amino acid residues or at least one amino acid residue from 131st amino acid to 133rd amino acid residues as measured from N terminal end is deleted.~~